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Objectives: To evaluate the in-hospital out-
come of STEMI (ST elevation myocardial infarc-
tion) patients admitted to Swiss hospitals between
2000 and December 2007, and to identify the pre-
dictors of in-hospital mortality and major cardiac
events.
Methods: Data from the Swiss national reg-
istry AMIS Plus (Acute Myocardial Infarction and
Unstable Angina in Switzerland) were used. All
patients admitted between January 2000 and De-
cember 2007 with STEMI or a new LBBB (left
bundle branch block) were included in the reg-
istry.
Result: We studied 12026 STEMI patients
admitted to 68 hospitals. The mean age was 64
± 13 years and 73% of the patients were male. In-
cidence of in-hospital death was 7.6% in 2000 and
6% in 2007. Reinfarction fell from 3.7% in 2000
to 0.9% in 2007. Thrombolysis decreased from
40.2% in 2000 to 2% in 2007. Clinical predictors
of mortality were: age >65 years, Killips class III
or IV, diabetes, Q wave myocardial infarction (at
presentation). Patients undergoing percutaneous
coronary intervention (PCI) had lower mortality
and reinfarction rates (3.9% versus 11.2% and
1.1% versus 3.1% respectively, p <0.001) over
time, although their numbers increased from
43% in 2000 to 85% in 2007. Patients admitted to
hospitals with PCI facilities had lower mortality
than patients hospitalised in hospitals without it,
but the demographic characteristics differ widely
between the two groups.
Both in-hospital mortality and reinfarction
decreased significantly over the time, parallel to
an increased number of PCI. PCI was also the
strongest predictor of survival.
Conclusion: In-hospital mortality and reinfarc-
tion rate have decreased significantly in Swiss
STEMI patients in the last seven years, parallel to
a significant increase in the number of percuta-
neous coronary interventions in addition to med-
ical therapy. Outcome is not related to the site of
admission but to PCI access.
Key words: myocardial infarction; angioplasty,
STEMI, PCI
Summary
Introduction
Reperfusion and prompt restoration of ante-
grade coronary blood flow results in myocardial
salvage and improved left ventricular function and
survival [1–3]of patients with acute myocardial in-
farction. Both thrombolytic therapy and percuta-
neous coronary intervention (PCI) are used to
open the infarct-related artery [4–6]. Several ran-
domised trials favour PCI over thrombolysis [7–
16], especially in high risk patients [11, 17] due to
a higher patency rate, less reocclusion, recurrent
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ischaemia, reinfarction, and stroke [18–21].
Thrombolysis and medical management remain
the first choice treatment in some hospitals with-
out PCI capabilities, because of strategic con-
straints. Previous studies have shown that on site
PCI is a major determinant of patient manage-
ment. However, it is still an open question
whether the outcome of patients admitted to hos-
pitals with or without PCI capability is the same
or not, merely because the strategy and the infra-
structure are different.
We evaluated the Swiss STEMI (ST elevation
myocardial infarction) patients over time to de-
tect change in management (in line with the
evolving guidelines) and possibly in their progno-
sis. We also evaluated the clinical predictors of
in-hospital mortality, reinfarction and stroke.
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Methods
Data from the Swiss national registry on myocardial
infarction AMIS Plus were used.
The AMIS Plus Registry
Since 1997 this Swiss prospective national registry
has collected data from patients admitted with a definitive
diagnosis of acute coronary syndrome in Switzerland
(AMIS Plus). It is a prospective data bank monitored by a
Data Centre (Institute of Social and Preventive Medicine
at the University of Zürich) providing blinded data of
Swiss STEMI and non-STEMI patients. It is a complete
cohort of Swiss patients. Data are collected by an inter-
net- and/or paper-based questionnaire of 140 questions,
related to patient history, clinical parameters, previous
medical history, laboratory parameters, in-hospital and
discharge treatment, hospitalisation outcome and desti-
nation at discharge. The questionnaire is completed by
physicians and research nurses and has been described
previously [22].
Patients are enrolled in the registry on the basis of
final diagnosis, which must comply with one of the fol-
lowing three definitions: acute myocardial infarction
(symptoms or ECG changes compatible with acute coro-
nary syndrome, or both, and cardiac enzymes (total crea-
tine kinase (CK) or CK-MB) at least twice the upper limit
of normal range); acute coronary syndrome with mini-
mum necrosis (symptoms or ECG changes compatible
with acute coronary syndrome, or both, and cardiac en-
zymes (total CK or CK-MB) lower than twice the upper
limit of normal range, and positive troponins); and unsta-
ble angina (symptoms or ECG changes compatible with
acute coronary syndrome, or both, and normal cardiac en-
zymes). Cases that are of unclear or non-cardiac cause are
not included.
For this article we analyzed only patients with
STEMI.
The project is led by a Steering Committee and was
approved by the Supraregional Ethical Committee for
Clinical Studies and the Swiss Board for Data Security.
Study population
Between January 2000 and December 2007, patients
with STEMI or new left bundle branch block (LBBB)
were included in the registry. These patients were filtered
out of the AMIS Plus collective according to the dis-
charge diagnosis. American Heart Association/American
College of Cardiology (AHA/ACC) guidelines were fol-
lowed for patient management. Physicians were allowed
to use thrombolysis and/or PCI in both types of hospital
when needed. Patients hospitalised in establishments
without PCI facilities had to be transferred for PCI.
Patient characteristics
Demographic data, clinical variables, procedures,
and events were collected at admission and during the
hospital stay by physicians and dedicated nurses.
Statistics
All analyses were performed by the AMIS Plus Data
Centre. All categorical measures are reported as counts
with percentage and valid values. Pearsons chi-square
were used for group comparisons. The chi-square tests
were two-sided.All p values were two-sided and were con-
sidered significant if <0.05. A multivariate logistic model
was used to determine in-hospital mortality predictors
from the following set of variables: admission year; age;
sex; systolic and diastolic blood pressures; heart rate; his-
tory of arterial hypertension; history of dyslipidaemia;
history of diabetes; current smoking status; cardiopul-
monary resuscitation before admission; defibrillation/car-
dioversion before admission; Killip class at hospital ad-
mission (class I as reference category); delay between
symptom onset and admission to hospital >6 hours; Q
waves on initial ECG; left bundle branch block on initial
ECG; ST segment elevation on initial ECG; thromboly-
sis; primary PCI, cath-lab at hospital of admission. Sepa-
rate univariate logistical models were first fitted for each
variable and then backwards elimination with a signifi-
cance level of 0.05 was performed.We represent in tables
3 and 4 only the significant predictors of death and major
adverse cardiac events (MACE). Missing data are given in
the tables and are not included in the analysis.
Results
Baseline characteristics
Patient demographics and characteristics are
presented in table 1. A total of 12026 patients
(73% male) with a mean age of 64 ± 13 years were
treated for STEMI and included in the database.
In-hospital mortality was 6.9%, reinfarction 1.9%
and stroke 1% (table 2). The incidence of death,
reinfarction and stroke declined significantly over
time from 7.6% in 2000 to 6.5% (p = 0.004)
in 2007 for mortality, and from 3.7% to 1%
(p <0.001) for reinfarction. The incidence of
stroke decreased over time from 1.8% in 2000 to
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The AMIS Plus registry is a unique ongoing
multicentre project assessing management of
acute coronary syndromes in Switzerland. In-hos-
pital mortality and incidence of reinfarction de-
crease significantly as the number of PCI rises.
This confirms the benefit of aggressive manage-
ment of STEMI patients. In-hospital mortality
was 6.9%, which is comparable with other Euro-
pean registries (7% mortality in the Euro Heart
survey and GRACE [26, 27], 10.4% by MINAP
[28], 14% for the Danish registry [29]). Classical
clinical predictors of mortality were as in previous
trials [30]. As expected, reperfusion (thrombolysis
and PCI) was associated with a better outcome.
We confirm the impact of PCI facilities on reper-
fusion strategies. Availability of a catheterisation
laboratory will of course favour the use of primary
PCI, with some benefit to the outcome. Our find-
ings are in agreement with other observational
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0.8% in 2007 (p = 0.04). The percentage of
patients treated by PCI increased from 43% to at-
tain the high percentage of 85% in 2007.
Patient management is shown in figure 1.
Medical treatment without reperfusion was used
in 20%, thrombolysis alone in 7%, primary PCI
in 65% and PCI in addition to thrombolysis (fa-
cilitated PCI) in 8%. Patients admitted to hospi-
tals without PCI facilities were more prone to re-
ceive thrombolysis (23% versus 9%) than those
admitted to hospitals with PCI facilities. PCI was
more often used in hospitals with PCI facilities in
2000 (67% versus 27%) but this difference was
reduced in 2007 (94% versus 71%).Mortality and
reinfarction rate were higher in hospitals without
catheterisation facilities (table 2), although the
population was not fully comparable (mean age
65 ± 11 years versus 63 ± 13 years (p <0.001).
The use of thrombolysis fell from 40.2% in
2000 to 2% in 2007.
Multivariable analysis for in-hospital death
and MACE are presented in tables 3 and 4. Age
>65, diabetes, Killip class III-IV, Q wave MI (at
presentation) and no PCI were the most signifi-
cant predictors of death and MACE.
Site of hospitalisation (in-house PCI facilities
or not) is not a predictor of death (OR 1.1, 95%
CI 0.9–1.3) or MACE (OR 0.9, 95% CI 0.8–1.1).
Other variables entered (see the statistics section)
were not significant predictors.
The difference in mortality and reinfarction
is not related to the hospital type but to access to
PCI. Reperfusion (PCI and thrombolysis) have a
significant positive impact on survival.
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N 12026
Males 8828 (73%)
Mean age 64 ± 13 years
Killip I-II 11130 (93%)
Killip III-IV 845 (7%)
Q waves (at admission) 1971 (16.8%)
Hypertension 6200 (54.7%)
History of CAD 5155 (30.2%)
Diabetes 2128 (18.5%)
Current smoker 4711 (41.7%)
Dyslipidaemia 5873 (54.9%)
CAD: coronary heart disease
Table 1
Baseline
characteristics.
Table 2
Patients outcome.
All hospitals Hospitals without Hospitals with P value
24 h PCI on site 24 h PCI on site
In-hospitality mortality 6.9% 8.3% 5.8% <0.001
Reinfarction 1.9% 2.8% 1.3% <0.001
Stroke 1.1% 0.9% 1.2% 0.104
Figure 1
Management of patients.
Figure 2
Evolution of PCI, mortality and reinfarction from 2000
to 2007.
Discussion
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registries [13, 21, 23–25]. In the GRACE registry
[25] the incidence of in-hospital death was the
same between patients treated in hospitals with or
without catheterisation facilities, but this registry
tested hospital type and not strategy. A different
conclusion arises from the recent Swedish reg-
istry [31] on long-term outcome of patients with
STEMI. A significant reduction in short- and
long-term mortality and reinfarction was found
when PCI was compared with thrombolysis. We
show that on-site PCI is not correlated with a bet-
ter outcome, but that PCI itself has a favourable
impact on mortality and reinfarction. Clearly, ac-
cess to invasive facilities changes the prognosis of
Swiss patients with STEMI. Efforts have been
made to improve the proportion of patients trans-
ferred from small to larger hospitals with PCI fa-
cilities for invasive treatment, and over time the
number of these patients increased. This corre-
lated with a reduction in mortality and reinfarc-
tion. In addition, we noted that 32% of patients
hospitalised in establishments without PCI did
not benefit from any type of revascularisation,
compared to 10% of patients hospitalised in es-
tablishments with PCI. Even if this is consistent
with other recent registries [21, 23, 25], improve-
ments can be made in the application of guide-
lines and creation of networks to standardise the
management of patients with STEMI throughout
Switzerland.
Since the AMIS registry is not focused on
“lytic eligible patients”, it provides real life infor-
mation and we would not expect 100% access to
reperfusion strategies. This is also reported by
other groups, e.g., in the DANAMI-2 trial, where
only 37% of the cohorts screened were finally in-
cluded [32]. The differences in terms of reperfu-
sion strategy between two types of hospital
changed over time, more patients being trans-
ferred for PCI from small hospitals with a signifi-
cant decrease in mortality.
We conclude that Swiss STEMI patients still
have a significant incidence of complications and
that management could still be improved by de-
creasing the time to reperfusion and especially
PCI (facilitated communication and teamwork
between hospitals). Education of the public is also
needed to shorten the time between chest pain
and reperfusion.
Study limitations
In essence the AMIS Plus is an observational
registry; patients were not randomised to institu-
tions with or without cardiac catheterisation facil-
ities. It is recorded on a voluntary basis and may
have been a cause of undetected bias.
Our analysis suffers the limitations of multi-
variable evaluation, designed to correct raw re-
sults according to differences in baseline charac-
teristics.
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Table 3
Multivariate analysis
of predictors
of death.
OR 95% CI P value
PCI 0.5 0.4–0.6 <0.001
Thrombolysis 0.7 0.5–0.9 0.008
Killip III–IV 8.3 6.7–10.3 <0.001
Age >65 years 3.6 2.8–4.5 <0.001
Diabetes 1.5 1.2–1.8 <0.001
LBBB 1.3 1.0–1.7 0.043
Q waves 1.3 1.0–1.6 0.030
>6 h delay 0.8 0.6–1.0 0.022
Table 4
Multivariate analysis
of the composite end
point predictors of
major adverse car-
diac events (death,
reinfarction, stroke).
OR 95% CI P value
PCI 0.6 0.5–0.7 <0.001
Thrombolysis 0.8 0.6–1.0 0.057
Age >65 years 2.8 2.3–3.3 <0.001
Killip III–IV 6.9 5.7–8.5 <0.001
Q waves 1.5 1.2–1.8 <0.001
Diabetes 1.5 1.2–1.8 <0.001
LBBB 1.2 1.0–1.6 0.083
>6 h delay 0.9 0.7–1.0 0.128
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